Analyst Nadine Sarwat sees Cronos and Tilray as ‘fairly valued’ and Canopy Growth as ‘meaningfully overvalued.’
Cannabis Watch: Bernstein launches coverage of Canada’s Tilray, Cronos and Canopy Growth but stops short of any buy ratings
by
Tags:
Analyst Nadine Sarwat sees Cronos and Tilray as ‘fairly valued’ and Canopy Growth as ‘meaningfully overvalued.’
by
Tags: